Overview
Pulmonary hypertension (PH) is a serious and potentially life-threatening complication that affects a significant subset of patients with congenital heart disease. Whether caused by left-to-right shunting (Eisenmenger syndrome), post-operative pulmonary vascular remodeling, or associated lung disease, PH demands specialized evaluation and targeted treatment.
PH in Congenital Heart Disease
Pulmonary hypertension in CHD can develop through multiple pathways. Unrepaired left-to-right shunts expose the pulmonary vasculature to chronic volume and pressure overload, eventually causing irreversible vascular remodeling (Eisenmenger physiology). Post-surgical patients may develop PH from residual hemodynamic lesions, pulmonary vein stenosis, or diastolic dysfunction. Accurate classification of the PH mechanism is essential for selecting appropriate therapy.
Diagnostic Evaluation
Comprehensive PH evaluation includes right heart catheterization, vasoreactivity testing, high-resolution CT, ventilation-perfusion scanning, pulmonary function testing, and six-minute walk assessment. In CHD patients, catheterization data must be interpreted in the context of the underlying anatomy — shunt calculations, Qp:Qs ratios, and pulmonary vascular resistance indexing are critical for accurate diagnosis.
Targeted Therapies
PH-specific therapies include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs, and soluble guanylate cyclase stimulators. Treatment selection depends on PH classification, functional class, hemodynamic severity, and the presence or absence of operable CHD. Combination therapy is often required, and response is monitored through serial functional assessments and hemodynamic measurements.
Living with Pulmonary Hypertension
PH is a chronic condition requiring ongoing management, lifestyle adaptation, and psychosocial support. We counsel patients on activity modification, altitude precautions, pregnancy avoidance (in severe cases), and emergency planning. A strong patient-provider partnership is essential for maintaining quality of life and optimizing long-term outcomes.
Who Is This For?
- Patients with CHD-associated pulmonary hypertension or Eisenmenger syndrome
- Adults with unexplained dyspnea or exercise intolerance and a history of CHD
- Patients already on PH therapy needing expert medication management
- Providers referring patients for pulmonary hypertension workup